Editas And Allergan Launch World’s First In Vivo CRISPR Trial
Rare Blindness Targeted
Partners pioneer approach in rare disease in what will be pivotal year for CRISPR and gene-editing technologies.
You may also be interested in...
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.